Corcym has announced the first use of its Perceval Plus Lancelot sutureless aortic valve in a US patient.
The Perceval Plus Lancelot valve introduces a next-generation manufacturing process intended to enhance valve performance and durability, a press release from the company states. It features precision laser-cut bovine pericardial leaflets, a manufacturing approach designed to improve the accuracy and consistency of the valve structure.
Following the procedure, which was performed at a US centre in September 2025, the patient has recovered and returned to everyday activities.
“At Corcym, innovation begins and ends with the patient,” said Christian Mazzi, CEO of Corcym. “The first US implantation of our Perceval Plus Lancelot valve reflects our commitment to advancing surgical technologies that support cardiac surgeons and improve outcomes for patients with structural heart disease.”
“The introduction of next-generation sutureless valve technology represents an important step forward in surgical options for patients with aortic valve disease,” said Robert Gallegos, chief of cardiac surgery at CHI Health (Omaha, USA) and proctor for the procedure. “Innovations like this can help surgeons perform procedures efficiently while supporting strong valve performance and long-term outcomes for patients.”
“This kind of innovation reflects the continued evolution of sutureless surgical valve therapy,” said Ali J Khiabani, cardiac surgeon at CHI Health (Omaha, USA). “Precision in valve design may help improve how the valve functions, potentially improving blood flow and gradients across the valve, and ultimately better long-term outcomes for patients undergoing bioprosthetic aortic valve replacement.”
The Perceval platform has been used by cardiac surgeons worldwide for almost 20 years and is designed to enable sutureless implantation, which simplifies surgical procedures and supports minimally invasive approaches to aortic valve replacement, Corcym’s press release states.
